Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | PEPD | P12955 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14311389 | 0.86 | KIF11 (0.51) | KIF11GLAPEPDALDH1A1NPC1 | |
| SCHEMBL13816275 | 0.79 | CYP3A4 (0.56) | ALDH1A1NPC1GAAMAPTMEN1 | |
| SCHEMBL22399078 | 0.79 | GAA (0.68) | ALDH1A1GAAMAPTLMNAMEN1 | |
| SCHEMBL19699681 | 0.77 | TGM2 (0.54) | LMNA | |
| SCHEMBL8458858 | 0.75 | HTT (0.57) | ALDH1A1NPC1GAAMAPTLMNA | |
| SCHEMBL5533028 | 0.75 | KIF11 (0.89) | KIF11GLAPEPDALDH1A1NPC1 | |
| SCHEMBL24346009 | 0.74 | EPHX1 (0.57) | ALDH1A1NPC1MEN1KMT2AHTT | |
| SCHEMBL12569599 | 0.73 | FADS1 (0.61) | KIF11GLAGAAMAPTGFER | |
| SCHEMBL29639822 | 0.73 | FADS1 (0.61) | KIF11GLAGAAMAPTGFER | |
| SCHEMBL11310009 | 0.73 | ALDH1A1 (0.42) | KIF11GLAALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541383-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080085891-A1 | Asthma and allergic inflammation modulators | FU ZICE | 2008-04-10 | — | — | US | disclosed |
| US-7321001-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085891-A1 | Asthma and allergic inflammation modulators | IL5, TSLP, CYSLTR2 | KIF11 4275/4885GLA 3041/4885PEPD 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.